Amgen, Merck To Test New Immunotherapy Combination
This article was originally published in Scrip
Amgen Inc. and Merck & Co. Inc. inked a collaboration agreement to test their antibody therapies Blincyto (blinatumomab) and Keytruda (pembrolizumab) in patients with diffuse large B-Cell lymphoma (DLBCL) in a Phase Ib/III clinical trial.
You may also be interested in...
The next two years will be important as Amgen looks to deliver on its BiTE platform beyond the first approved drug, Blincyto. SVP David Reese lays out the path forward, including solid tumor opportunities and next-generation BiTEs.
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.